CYCAD-1: First-in-human AZD8421 alone or in combination in advanced solid tumors

Phase 2, open-label trial of AZD8421 in breast cancer, ovarian cancer and Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events, serious adverse events, and dose-limiting toxicities, Clinically significant changes from baseline in laboratory parameters, vital signs, and ECGs and 1 more. Planned start Apr 2024; status: authorised.